They found that CD28.ζ-CAR molecules shuttle through the immune synapse quickly, working within minutes to kill cancer cells. This enabled fast CAR T cell recovery and a mastery of “serial ...

Did it push the human immune system into overdrive, causing a catastrophic immune response? The compound, TGN1412, was developed by TeGenero, a small biotechnology firm based in Wurzburg, Germany.

Rondo Therapeutics Publishes Preclinical Data on RNDO-564, a Novel CD28 x Nectin-4 Co-Stimulatory Bispecific Antibody for the Treatment of Bladder Cancer -RNDO-564 is designed to deliver safe and ...

Rondo Therapeutics Announces Collaboration with Lilly to Develop Novel CD28 Bispecific Antibodies for Solid Tumors – Lilly is granted exclusive worldwide rights to develop a CD28-co-stimulatory ...

A CAR with specificity to MUC-1 has also been generated using the SM3 antibody with intracellular signaling motifs of CD28, OX40 and CD3ζ. [151] ...

Dysregulated AKT phosphorylation following CD28 co-stimulation Mechanistically, the study identified that PP2A maintains CD8+ T cell effector functions through modulation of the PI3K-AKT signaling ...

Repertoire Immune Medicines Inc. has entered into a collaboration and license agreement with Genentech Inc., a member of the Roche Group, to discover and develop innovative T cell-targeted immune ...